Sanofi has entered a research collaboration and license agreement with Evotec and Apeiron Biologics to discover and develop first-in-class small molecule-based immuno-oncology therapies to treat solid and hematological cancers by enhancing the anti-tumor activity of the human immune system.

Boehringer Ingelheim and Circuit Therapeutics have announced a second collaboration using Circuit's proprietary optogenetics technology platform. This new three-year collaboration will focus on investigating metabolic disorders with the aim of developing novel medicines to improve the treatment of obesity and associated diseases.

Today, Roche welcomed 100 European university students from 34 countries studying science and art to the Salzburg Festival, the world's largest and most prestigious festival of music and drama. The annual Roche Continents week offers highly talented undergraduate and graduate students the opportunity to explore sources of inspiration at the intersection of science and music through structured workshops and challenges.

AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.

Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).

Bristol-Myers Squibb Company (NYSE:BMY) has announced the establishment of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.